Iradimed Corporation (NASDAQ:IRMD) Short Interest Update

Iradimed Corporation (NASDAQ:IRMD) saw a large increase in short interest during the month of December. As of December 31st, there was short interest totalling 124,100 shares, an increase of 18.2% from the December 15th total of 105,000 shares. Currently, 1.6% of the company’s stock are short sold. Based on an average daily volume of 39,400 shares, the short-interest ratio is presently 3.1 days.

Insider Buying and Selling at Iradimed

In other Iradimed news, CFO John Glenn sold 2,500 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $54.18, for a total value of $135,450.00. Following the sale, the chief financial officer now directly owns 4,383 shares of the company’s stock, valued at approximately $237,470.94. This represents a 36.32 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Insiders own 37.10% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Jacobs Levy Equity Management Inc. boosted its holdings in shares of Iradimed by 1.9% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 24,779 shares of the medical equipment provider’s stock valued at $1,246,000 after buying an additional 472 shares in the last quarter. Huntington National Bank boosted its holdings in shares of Iradimed by 51.3% in the 3rd quarter. Huntington National Bank now owns 1,487 shares of the medical equipment provider’s stock valued at $75,000 after buying an additional 504 shares in the last quarter. Cim LLC boosted its holdings in shares of Iradimed by 5.9% in the 2nd quarter. Cim LLC now owns 10,089 shares of the medical equipment provider’s stock valued at $464,000 after buying an additional 561 shares in the last quarter. Kings Path Partners LLC boosted its holdings in shares of Iradimed by 2.3% in the 3rd quarter. Kings Path Partners LLC now owns 24,570 shares of the medical equipment provider’s stock valued at $1,236,000 after buying an additional 562 shares in the last quarter. Finally, Gladius Capital Management LP boosted its stake in Iradimed by 126.6% during the 3rd quarter. Gladius Capital Management LP now owns 1,727 shares of the medical equipment provider’s stock worth $87,000 after purchasing an additional 965 shares during the period. Institutional investors and hedge funds own 92.34% of the company’s stock.

Iradimed Stock Performance

Shares of NASDAQ:IRMD traded up $0.81 during trading hours on Friday, reaching $59.17. The stock had a trading volume of 50,168 shares, compared to its average volume of 37,022. The firm’s 50 day moving average is $54.76 and its 200-day moving average is $50.17. Iradimed has a 1 year low of $40.18 and a 1 year high of $59.31. The stock has a market capitalization of $749.68 million, a price-to-earnings ratio of 40.53 and a beta of 0.81.

Iradimed Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, November 25th. Stockholders of record on Friday, November 15th were issued a $0.15 dividend. This represents a $0.60 annualized dividend and a dividend yield of 1.01%. The ex-dividend date of this dividend was Friday, November 15th. Iradimed’s payout ratio is 41.10%.

About Iradimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.